Free Trial
→ What Elon Musk's Cybercab Reveal Could Mean for Investors (From Brownstone Research) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$1,368.85
-3.5%		$1,207.75
$850.51
▼
$1,453.00
$1.29T0.42.95 million shs4.74 million shs
Natera, Inc. stock logo
NTRA
Natera
$363.76
-7.0%		$380.30
$181.00
▼
$437.41
$52.43B1.551.43 million shs3.07 million shs
10 Best Stocks to Own in Fall 2026 Cover
10 Best Stocks to Own in Fall 2026

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
+0.67%+9.99%+23.83%+18.98%+56.44%
Natera, Inc. stock logo
NTRA
Natera
+0.62%-7.87%-8.13%+47.35%+99.05%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$1,368.85
-3.5%		$1,207.75
$850.51
▼
$1,453.00
$1.29T0.42.95 million shs4.74 million shs
Natera, Inc. stock logo
NTRA
Natera
$363.76
-7.0%		$380.30
$181.00
▼
$437.41
$52.43B1.551.43 million shs3.07 million shs
10 Best Stocks to Own in Fall 2026 Cover
10 Best Stocks to Own in Fall 2026

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
+0.67%+9.99%+23.83%+18.98%+56.44%
Natera, Inc. stock logo
NTRA
Natera
+0.62%-7.87%-8.13%+47.35%+99.05%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.86
Moderate Buy$1,404.142.58% Upside
Natera, Inc. stock logo
NTRA
Natera
2.83
Moderate Buy$394.318.40% Upside

Current Analyst Ratings Breakdown

Latest LLY and NTRA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/2/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetOverweight$1,440.00 ➝ $1,600.00
10/30/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeBuy (B+) ➝ Buy (B)
10/30/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Argus logo
Argus
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetBuy$1,300.00 ➝ $1,550.00
10/30/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetBuy$1,425.00 ➝ $1,625.00
10/30/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
BMO Capital Markets logo
BMO Capital Markets
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingOutperform$1,650.00
10/30/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Bank of America Corporation logo
Bank of America
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy$1,497.00
10/30/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetOverweight$1,330.00 ➝ $1,500.00
10/30/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Truist Financial Corporation logo
Truist Financial
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy$1,376.00 ➝ $1,612.00
10/30/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetOverweight$1,500.00 ➝ $1,650.00
10/30/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetBuy$1,600.00 ➝ $1,650.00
10/27/2026
Natera, Inc. stock logo
NTRA
Natera
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetBuy$320.00 ➝ $430.00
(Data available from 11/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$65.18B19.76$24.41 per share56.07$42.81 per share31.97
Natera, Inc. stock logo
NTRA
Natera
$2.31B22.74N/AN/A$12.38 per share29.38
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$20.64B$30.8144.4327.361.7631.90%86.76%22.03%N/A
Natera, Inc. stock logo
NTRA
Natera
-$208.16M-$1.36N/AN/AN/A-7.11%-11.38%-7.87%11/5/2026 (Estimated)

Latest LLY and NTRA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/5/2026Q3 2026
Natera, Inc. stock logo
NTRA
Natera
-$0.2812-$0.42-$0.1388-$0.42$707.54 million$793.98 million
10/29/2026Q3 2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$5.71$7.48+$1.77$7.22$22.58 billion$24.40 billion
8/6/2026Q2 2026
Natera, Inc. stock logo
NTRA
Natera
-$0.4939-$0.47+$0.0239-$0.47$661.24 million$752.75 million
8/5/2026Q2 2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.40$8.38+$1.98$7.94$20.82 billion$22.97 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.920.51%+15.18%22.46%11 Years
Natera, Inc. stock logo
NTRA
Natera
N/AN/AN/AN/AN/A

Latest LLY and NTRA Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
10/26/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
quarterly$1.730.54%11/13/202611/13/202612/10/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
1.17
1.39
1.00
Natera, Inc. stock logo
NTRA
Natera
N/A
3.00
2.85

Institutional Ownership

CompanyInstitutional Ownership
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%
Natera, Inc. stock logo
NTRA
Natera
99.90%

Insider Ownership

CompanyInsider Ownership
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.14%
Natera, Inc. stock logo
NTRA
Natera
5.05%
CompanyEmployeesShares OutstandingFree FloatOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
50,000940.74 million939.43 millionOptionable
Natera, Inc. stock logo
NTRA
Natera
6,140144.14 million136.87 millionOptionable

Recent News About These Companies

Natera Reports Third Quarter 2026 Financial Results
 |  businesswire.comhttps://www.businesswire.com/news/home/20261105041347/en/natera-reports-third-quarter-2026-financial-results/
Natera stock heads into November 5 earnings release
November 5 at 9:45 AM  |  ad-hoc-news.deA
Natera (NASDAQ:NTRA) Stock: Insider John Fesko Sells 302 Shares
November 5 at 6:37 AM  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-ntra-insider-buying-and-selling-2026-11-05/
18,255 Shares of Natera, Inc. $NTRA Bought by Mirae Asset Global Investments Co. Ltd.
November 5 at 4:56 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-18255-shares-of-natera-inc-ntra-bought-by-mirae-asset-global-investments-co-ltd-2026-11-05/
Natera (NASDAQ:NTRA) Shares Break Above Fifty Day Moving Average After Insider Selling
November 5 at 2:01 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31178948
Insider Selling: Natera (NASDAQ:NTRA) Insider Sells $120,803.02 in Stock
November 4 at 11:08 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-insider-selling-natera-nasdaq-ntra-insider-sells-12080302-in-stock-2026-11-04/
Insider Selling: Natera (NASDAQ:NTRA) CFO Sells 325 Shares of Stock
November 4 at 11:08 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-insider-selling-natera-nasdaq-ntra-cfo-sells-325-shares-of-stock-2026-11-04/
Natera (NASDAQ:NTRA) Stock: Insider Michael Burkes Brophy Sells 470 Shares
November 4 at 11:08 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-natera-nasdaq-ntra-stock-insider-michael-burkes-brophy-sells-470-shares-2026-11-04/
Natera (NASDAQ:NTRA) Insider Sells 3,419 Shares of Company Stock
November 4 at 11:07 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-natera-nasdaq-ntra-insider-sells-3419-shares-of-company-stock-2026-11-04/
Natera (NASDAQ:NTRA) CEO Sells $1,565,251.80 in Stock
November 4 at 11:07 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-natera-nasdaq-ntra-ceo-sells-156525180-in-stock-2026-11-04/
Natera stock gets Medicare coverage boost for Signatera in HCC
November 4 at 6:17 PM  |  ad-hoc-news.deA
Natera stock gains Medicare coverage milestone for Signatera
November 4 at 8:32 AM  |  ad-hoc-news.deA
Natera, Inc. $NTRA Stock: Torray Investment Partners LLC Trims Stake
November 4 at 5:51 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-natera-inc-ntra-stock-torray-investment-partners-llc-trims-stake-2026-11-04/
Natera (NTRA) to report earnings tomorrow: here is what to expect
November 4 at 3:31 AM  |  financialcontent.comF
Aware Super Pty Ltd as trustee of Aware Super Buys 16,018 Shares of Natera, Inc. $NTRA
November 4 at 3:20 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-aware-super-pty-ltd-as-trustee-of-aware-super-buys-16018-shares-of-natera-inc-ntra-2026-11-04/
Natera, Inc. (NASDAQ:NTRA) Stock Has Consensus Target Price of $394.31
November 4 at 3:03 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31177350
Natera, Inc. (NASDAQ:NTRA) Stock Has Consensus Price Target of $394.31 According to Brokerages
November 4 at 2:28 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-natera-inc-nasdaq-ntra-stock-has-consensus-price-target-of-39431-according-to-brokerages-2026-11-04/
Natera (NASDAQ:NTRA) Shares Cross Above 50 Day Moving Average Following Insider Selling
November 3 at 12:19 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-natera-nasdaq-ntra-shares-cross-above-50-day-moving-average-following-insider-selling-2026-11-03/
Natera stock faces November 5 test after fresh oncology evidence
November 3 at 5:30 PM  |  ad-hoc-news.deA
Natera (NASDAQ:NTRA) CFO Michael Burkes Brophy Sells 1,178 Shares of Stock
November 3 at 4:09 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31175982
Natera (NASDAQ:NTRA) Stock: Insider Michael Burkes Brophy Sells 1,178 Shares
November 3 at 4:07 AM  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-ntra-insider-buying-and-selling-2026-11-03/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Salesforce cloud logo in a futuristic tech setting, highlighting CRM enterprise software and AI platform growth.
Salesforce Fuels AI Engine With $5.66B Braze Buyout
By Jeffrey Neal Johnson | October 21, 2026
White Tesla sports car parked at a launch site with rocket boosters visible against a sunset sky.
Tesla's Roadster Reveal Hints at 2 Much Bigger Moves
By Sam Quirke | October 19, 2026
Kalshi and Polymarket logos beside a smartphone showing a prediction market on the Chiefs winning the Super Bowl, with a football in the background.
Want Private-Market Access to Kalshi and Polymarket? Try This ETF
By Jessica Mitacek | October 8, 2026
Eli Lilly, Moderna, Guardant Health and Illumina Ride AI That Reads the Body
The AI Trade Just Moved Into Your Bloodstream, and 4 Healthcare Stocks Are Winning
By Bridget Bennett | October 19, 2026
Eli Lilly logo on a lab wall with injector pens, vials, and lab equipment in the foreground.
Eli Lilly’s First Full Medicare Quarter: Is Volume Still Outrunning Price Cuts?
By Nathan Reiff | November 1, 2026
Eli Lilly and Company stock logo

Eli Lilly and Company NYSE:LLY

$1,368.85 -49.14 (-3.47%)
Closing price 03:59 PM Eastern
Extended Trading
$1,361.00 -7.85 (-0.57%)
As of 04:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Natera stock logo

Natera NASDAQ:NTRA

$363.76 -27.27 (-6.97%)
Closing price 04:00 PM Eastern
Extended Trading
$291.99 -71.77 (-19.73%)
As of 04:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas